{
    "nct_id": "NCT05090371",
    "official_title": "A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)",
    "inclusion_criteria": "* Signed informed consent must be obtained prior to participation in the study.\n* Age 18-45 years\n* Diagnosis of RRMS per McDonald Criteria (2017)\n* EDSS 0-5.5 (Inclusive)\n* Able to obtain MRI and attend study visits at sites\n* Willing to use wearable device as specified in the protocol\n* Able to provide blood sample\n* On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening\n* No relapse reported within 6 months prior to Screening\n* Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 50 Years",
    "exclusion_criteria": "* Primary progressive or secondary progressive phenotype\n* Diseases other than multiple sclerosis responsible for the clinical or MRI presentation\n* Use of experimental or investigational drugs for MS within 2 years from Screening\n* Known sensitivity to gadolinium\n* Central Nervous System (CNS) anomalies that are better accounted for by another disease process\n* Known active malignancies\n* Active chronic disease (or stable but treated with immune therapy) of the immune system other than MS\n* Active infections including systemic bacterial, viral (including COVID-19) or fungal infections, known to have AIDS or tested positive for HIV antibodies\n* Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML\n* IgG or IgM levels below lower limit of normal (LLN) at Screening",
    "miscellaneous_criteria": ""
}